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lymphoma). All patients had biopsy-proven disease and got 
pre-treatment local and distant staging (Choline PET-CT, 
pelvic/prostatic MRI and bone scan). HDR-BT was performed 
by transperineal insertion of intraprostatic catheters under 
spinal anaesthesia and trans-rectal ultrasound guidance using 
an Ir-192 source. A total dose of 24 Gy to the whole gland 
was prescribed in two separate fractions of 12 Gy, 2-4 weeks 
apart. Dosimetric constraints for prostate and organ at risk 
(OAR) sparing were defined; we aimed at a prostate D90 > 
95% and a V100 > 85% while the urethral Dmax was kept < 120 
% and the D10 < 115 %; the rectal D2cc was kept <75 %. 
Patient reported genitourinary (GU) and gastro-intestinal (GI) 
symptoms according to the NCI.CTCv3 were assessed before 
HDR-BT and every 4-6 months afterward. 
 
Results: The median age of the pts was 68.5 (range 63-77) 
years; the pre-treatment PSA was 5.71 (range 0.067-11.04) 
ng/ml. The median interval from the end of the previous 
EBRT and HDR-BT was 8.75 (range 3-16 years) years. The 
median prostate D90 and V100 for the 26 HDR-BT fractions 
analysed were respectively 97.17 % and 86.7 % of the 
prescribed dose but in 4 pts the D90 was < 95 % and in 8 the 
V100 was < 85 %. The median urethral Dmax was 105.73 % 
and the median D10 was 94.71 %; the median D2cc for the 
rectum was 45.98 %. After a median follow-up of 13.9 (range 
2-28) months, acute GU grade 1 and 2 toxicities were 
reported in 4 and 3 pts respectively while one patient 
reported a grade 2 acute GI toxicity. Eleven pts were 
evaluable for late toxicities: five reported a late GU grade 1 
and two pts a grade 2 toxicity. Any late GI toxicity has been 
reported so far. Nine pts (69%) are biochemical disease-free 
while none of the 4 pts showing a rising PSA developed an 
intraprostatic relapse. 
 
Conclusion: HDR-BT in 2 fractions of 12 Gy may represent an 
interesting alternative for the management of pts with an 
isolated intraprostatic recurrence after EBRT and for 
challenging clinical situations when EBRT is contraindicated. 
The early toxicity profiles seem correct and clinical results 
promising. 
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Purpose or Objective: The aim is to compare OAR dosimetry 
for the nationally-adopted technique for PSB withexisting 
GEC-ESTRO and ABS guidelines. This modified MountSinai 
technique prescribes 160Gy to the prostate gland without a 
margin. Thedose volume constraints (DVCs) used are: 
urethra(UD30) < 181Gy and rectum (RV100) < 1cc.  
By comparing the institutional techniqueto international 
standards we aim to demonstrate if: 
i) All constraints perform similarly usingclinical plans. 
ii) Institutional plans would be consideredreasonable when 
GEC-ESTRO and ABS guidelines are applied. 
iii) The addition of GEC-ESTRO and ABS DVCsto institutional 
practice may be of clinical utility. 
 
Material and Methods: The first 50 PSB implants performed 
in Institution were retrospectively re-contoured as per ABS 
and GEC ESTRO recommendations in Variseed (version 8.0). A 
PTV with margin of 3mm was added to the prostate except 
posterior aspect. The prescribed dose was altered to 145Gy 
to the PTV, as per GEC-ESTRO and ABS guidelines. The GEC-
ESTRO and ABS DVCs were then applied. 
 
Results: The median prostate V100 was 95.34% for CUH (IQR 
95.34-97.66%) met by 58% of cases. The median V100 was 
94.17% for ABS and GEC-ESTRO (IQR 92.68-95.61%) met by 
36% of cases (p=0.007). The median D90 for CUH was 
175.46Gy (IQR 168.98-186.67Gy). The median D90 for GEC-
ESTRO and ABS was 159.08Gy (IQR 152.46-165.41Gy). 
D90>prescription dose was achieved by 92% for all groups. 
The median RV100 using the institutional technique was 
0.27cc (IQR 0.12-0.59cc) and the <1cc target was met by 92% 
of cases. The ABS rectal constraint is RV100<1.3cc, at day 30. 
The median ABS RV100 was 0.46cc (IQR 0.28-0.91cc) and the 
<1.3cc target was achieved in 88% of cases. The GEC-ESTRO 
rectal constraint D0.1<200Gy and D2cc≤145Gy were met by 
70% and 100% of the plans respectively. The median urethral 
UD30 using the institutional technique was 178.10Gy (IQR 
175.27-180.59Gy). The GEC-ESTRO urethral constraints of 
UD30<188.5Gy and D10<217.5Gy were met by 100% and 100% 
of plans respectively. The ABS urethral constraint UD5<150% 
was met by 98% and UD30<125% was met by 82% of cases. 
 
Conclusion: Comparing the Institutional DVCs for rectum and 
urethra with ABS and GEC-ESTRO guidelines shows that they 
are concordant. Institutional and ABS urethral constraint 
UD30 appears conservative when GEC-ESTRO urethral 
constraints are applied. While validated DVCs are vital for 
optimal prostate seed brachytherapy, prospective 
documentation of toxicities is crucial. 
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Purpose or Objective: The aim of this study is to examine if 
adjuvant hormonal therapy is needed for all of the high-risk 
prostate cancer patients treated with high dose rate-
brachytherapy (HDR-BT) combined with external beam 
radiotherapy (EBRT). 
 
Material and Methods: Between July 1999 and June 2010, 
121 patients considered as high-risk group (T stage > or = 2c, 
PSA > 20 ng/ml, or Gleason score (GS) > or = 8) were treated 
with HDR-BT and EBRT at Kochi Medical School Hospital in 
Japan. Patient age ranged from 52 to 82 (median 71) years 
old. Eighty-two patients had received neoadjuvant hormonal 
therapy, which was stopped at the beginning of radiotherapy 
in all cases. Patients were treated with EBRT to 40 Gy in 20 
fractions or 39 Gy in 13 fractions and HDR-BT to 18 Gy in 2 or 
3 fractions for prostate and seminar vesicle. Adjuvant 
hormonal therapy was not performed until biochemical 
failure or clinical recurrence became apparent. PSA failure 
was defined as the Phoenix definition of nadir + 2 ng/mL. The 
overall survival (OS) rates, disease-specific survival (DSS) 
rates, and biological relapse-free survival (bRFS) rates were 
estimated using the Kaplan-Meier method. Log-rank test and 
Cox proportional hazards regression analysis were used for 
univariate and multivariate analyses, respectively, to 
examine these factors in relation to bRFS: age, clinical T 
stage (cT), initial PSA level (iPSA), GS, needle core biopsy 
positive ratio (% core), and use of neoadjuvant hormonal 
therapy (NHT). Follow-up ranged from 4 years 3 months to 13 
years 3 months (median 6 years 10 months). 
 
Results: The 5-year OS, CSS, and bRFS rates were 91.3, 98.2, 
and 88.0%, respectively. The 7-year OS, CSS, and bRFS rates 
were 86.4, 98.2, and 88.0%, respectively. In log-rank test, 
the group with cT < or = 2b was superior to that with cT > or 
= 2c (p = 0.0297), and that with iPSA < or = 10 ng/mL was 
superior to that with iPSA > 10 ng/mL (p = 0.0137). On 
multivariate Cox regression analysis, cT remained an 
independent predictor of bRFS (hazard ratio, 3.82; 95% 
confidence interval [CI], 1.11-13.14; p = 0.0337). 
 
Conclusion: In the high risk prostate cancer group treated 
with HDR-BT followed by EBRT, the subgroup with cT < or = 
2b gained a good bRFS rate without adjuvant hormonal 
therapy. 
 
 
 
